Showing posts with label mesothelioma. Show all posts
Showing posts with label mesothelioma. Show all posts

Friday, April 23, 2010

Ins and Outs of Treating Malignant Mesothelioma

    A type of cancer with a name most individuals don’t even recognize, mesothelioma – asbestos-caused cancer – is not only a rare disease but also one that is extremely difficult to treat. All cancers provide challenges when to comes to fighting the disease, but mesothelioma treatment is tougher than most.

The disease’s long latency period is the culprit. Often latent for as long as 50 years, when mesothelioma is finally discovered, it has usually spread from its primary location – which is usually the pleura (lining of the lungs) – to other parts of the body, generally the abdomen and other nearby organs. These metastases limits options and, traditionally, meso patients are in for a long fight.

    Most often, oncologists who are experienced in the treatment of this asbestos-caused cancer recommend a course of multi-modal treatment, combining a few different kinds of therapies to best address the growing tumor and the debilitating symptoms of the disease. Surgery, especially the curative type – including pneumonectomy, the removal of a lung – is rarely prescribed in the treatment of mesothelioma because of the advanced stage at which the disease is diagnosed. In addition, these surgeries are rigorous, ripe with complications and demanding long recovery periods. The patient must be in otherwise excellent health to withstand the procedures. Instead, surgery is more often offered for palliative reasons, including procedures such as a pleurodesis, designed to stop the build-up of fluid in the space around the lungs.

Monday, August 3, 2009

What do you know about mesothelioma?

How many people do you know who have mesothelioma? The annual incidence of mesothelioma in the U.S. is approximately 3300 new cases per year. Fortunately, the incidence is declining because we've done a better job to control for asbestos exposure. However, many people live with a long history of asbestos exposure because of certain types of occupations.


From a public health standpoint, mesothelioma is a significant health burden because mesothelioma prognosis is often quite poor. The median survival of patients with mesothelioma is between 6 and 18 months. Considering that advances in modern medicine have not significantly improved survival, we're faced with an illness that we still can't treat very effectively. Mesothelioma is often classified into three broad histologic subtypes:

1. epithelioid,
2. sarcomatoid, and
3. biphasic (mixed)

Mesothelioma doesn't just occur in the chest. There are other forms, such as peritoneal mesothelioma that occurs in the abdominal space. This type often rapidly spreads within the abdomen and is causes problems as the disease affects abdominal organs. So what types of treatments are currently available? You have surgery, radiation, chemotherapy, and a variety of combinations. Recently, investigators have also been exploring the role of gene therapy. That's the area that I find most fascinating because we may potentially see some novel treatment approaches that combine gene expression profiling and prognostication. By engineering viruses to carry certain genes. For instance, the administration of AdHSVtk could transduce the tumor cells, enabling them to express viral thymidine kinase, and thus make them sensitive to the normally nontoxic antiviral drug ganciclovir. This type of bioengineering research sounds very interesting to me.

Tuesday, July 7, 2009

FDA Approves First Maintenance Drug Therapy for Advanced Lung Cancer


This isn't a new drug, but it's a new indication: "maintenance therapy of advanced or metastatic lung cancer." Alimta was originally approved in 2004 for mesothelioma. Here's the summary straight from the FDA:

The U.S. Food and Drug Administration has approved Alimta (pemetrexed), the first drug available for maintenance therapy of advanced or metastatic lung cancer.

Patients with cancer often receive maintenance therapy to prevent the disease from progressing after their tumor has shrunk or the disease has stabilized in response to chemotherapy. Alimta disrupts metabolic processes that are dependent on the B-vitamin folate, a necessary ingredient for cell replication.

“This drug represents a new approach in the treatment of advanced non-small cell lung cancer,” said Richard Pazdur, M.D., director, Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research. “Typically, patients whose tumors respond to chemotherapy do not receive further treatment after four-to-six chemotherapy cycles. This study demonstrates an advantage in overall survival in certain patients who received Alimta for maintenance therapy.”

Non-small cell lung cancer has several subtypes, including squamous cell, large cell, adenocarcinoma and mixed histology cancers. In a 600-patient clinical trial, people with predominantly squamous cell cancer did not benefit from Alimta. But those with other subtypes of non-small lung cancer survived an average 15.5 months following treatment compared with 10.3 months for patients who received an inactive substance (placebo). All patients in the study received standard medical care.

Reported adverse events included damage to blood cells, fatigue, nausea, loss of appetite, tingling or numbness in the hands and feet, and skin rash.

Alimta initially was approved in 2004 for the treatment of patients with mesothelioma, a cancer frequently related to asbestos exposure. The drug was later approved for the treatment of patients with non-small cell lung cancer whose disease worsened on prior chemotherapy drugs and also as an initial therapy for advanced non-small cell lung cancer.

Alimta is manufactured by Eli Lilly & Co. of Indianapolis.

It's exciting to see advances in cancer treatment that focus on new drugs, biologic agents, and combination approaches. The world of oncology is buzzing with new science and the application of technology such as nanotechnology and targeted molecular therapies. Will we ever discover a cure? I doubt that we'll ever see a magic pill that completely eliminates every type of cancer, but lung cancer is a a highly preventable cancer so hopefully we'll see improved efforts at prevention. The greatest public health impact will be made if we improve our preventive health efforts.